New research has evaluated 1,275 infants across five Australian states, suggests that clinical history and allergy testing alone are insufficient to accurately diagnose peanut allergy in young children.

A world-first national programme has found that more than one third of infants believed to have a peanut allergy may be able to safely reintroduce the food into their diets.
The research, led by Murdoch Children’s Research Institute (MCRI) and the National Allergy Centre of Excellence (NACE), involved 10 paediatric public hospitals across Australia. It found that 35 percent of infants with a recent history of a reaction to peanut and positive allergy tests showed no reaction during a supervised oral food challenge.
Dr Tim Brettig, senior research clinician with MCRI’s Population Allergy Group and ADAPT Medical Lead, said the findings demonstrated the importance of confirming suspected allergies before committing children to long-term treatment.
“We found more than one third of infants who were suspected to have peanut allergy based on their history and initial tests no longer reacted when they underwent a supervised food challenge,” he said. “Being able to identify those children early allows them to avoid an unnecessary allergy label and the burden of avoiding peanut.”
Confirming food allergies
The findings come from an evaluation of the ADAPT Peanut Oral Immunotherapy Program, launched by NACE in 2024 as the first programme of its kind for infants in Australian public hospitals outside a clinical trial setting.
Across 10 hospitals in five Australian states, researchers assessed 1,275 infants under 18 months old. Of these, 778 underwent supervised oral food challenges, in which progressively larger amounts of peanut were administered to establish whether they had an allergy.
This avoids repeating the programme’s purpose and gives the reader a clearer progression from the initiative to the research methodology.
Oral food challenges change allergy diagnoses
The supervised challenges also helped determine which infants could benefit from treatment. While 65 percent experienced an allergic reaction, including 12 percent who developed anaphylaxis, all reactions were safely managed by the clinical teams.
For those who reacted, peanut oral immunotherapy was offered to build tolerance through regular, controlled doses of peanut. Of these infants, 97.5 percent successfully began treatment, with starting doses informed by their challenge results.
Meanwhile, the 35 percent who showed no reaction were considered peanut tolerant and could have their allergy diagnosis removed, allowing them to introduce peanut into their diets in age-appropriate forms such as peanut butter.
Implications for allergy management
Professor Kirsten Perrett, MCRI Population Allergy Group Leader, NACE Director and ADAPT Program Lead, said the findings could influence how suspected peanut allergies are diagnosed and managed.
“Oral food challenges are not currently used routinely for every infant with suspected peanut allergy,” she said. “But our results show that clinical history and allergy testing alone were not enough to accurately diagnose peanut allergy in many cases. A supervised oral food challenge should be routinely considered to confirm the diagnosis before an infant starts oral immunotherapy.”
The researchers say families who suspect their baby has a peanut allergy should speak to their GP, who may refer them to a paediatric allergy specialist.



No comments yet